Alberto Papi: key facts
- Kind of voice
- Academic
- Role
- Professor and Chair of Respiratory Medicine at the University of Ferrara, and Director of the Respiratory Unit, CardioRespiratory Department, S. Anna University Hospital, Ferrara, Italy
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 3
- Most recently quoted
- 30 Sept 2026
“Across Europe, millions of people with asthma still experience reduced lung function, breathing difficulties, exacerbations and significant disruption to daily life due to uncontrolled disease. The CHMP positive opinion for Trixeo represents an important step forward, offering a potential new treatment option that could help reduce exacerbations and improve disease control for patients living with asthma independent of their prior exacerbation history.”
What Alberto Papi has said
“Every day, I see patients whose asthma remains uncontrolled despite maintenance treatment, leaving them with persistent symptoms like difficulty breathing and declining lung function and at risk of exacerbations, which can have serious health consequences. The approval of Trixeo in Europe as the first triple-combination therapy in a single inhaler for patients 12 years of age and older provides an important new treatment option that has been shown to improve asthma control and reduce future risk of exacerbations, regardless of exacerbation history.”
Professor and Chair of Respiratory Medicine at the University of Ferrara, and Director of the Respiratory Unit, CardioRespiratory Department, S. Anna University Hospital, Ferrara, Italy · Respiratory (asthma/COPD) · 29 Sept 2026 · Trixeo approved in the EU for the maintenance treatment of asthma ↗
“Exacerbations drive disease progression, healthcare costs, hospitalizations, and mortality”
Professor of respiratory medicine at the University of Ferrara in Ferrara, Italy · Respiratory (asthma/COPD) · 28 Sept 2026 · Rethinking Viral COPD by Targeting Triggers, Inflammation ↗
Where Alberto Papi has been quoted
- Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthmaastrazeneca.com · 30 Sept 2026
- Trixeo approved in the EU for the maintenance treatment of asthmaastrazeneca.com · 29 Sept 2026
- Rethinking Viral COPD by Targeting Triggers, Inflammationmedscape.com · 28 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.